Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Selpercatinib

47ed4463-3042-507b-943f-df918f9edad2 · FDA Approved · targets RET

Selpercatinib

MeasuredReference

Selpercatinib targets RET, FLT4_VEGFR3, C_KIT. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

RETFLT4_VEGFR3C_KITFLT1_VEGFR1FLT3

Top hallmarks

  • tumor promoting inflammation4.9k
  • proliferation3.7k
  • evading apoptosis3.6k

Top pathways disrupted

  • pi3k akt mtor signaling9.0k
  • apical junction8.7k
  • allograft rejection8.2k

Resistance landscape — Selpercatinib

MeasuredReference

10 known oncogenic variants exist on Selpercatinib's top targets — see detail for inhibition impact.

Open in new tab